{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:39Z","timestamp":1740106899086,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T00:00:00Z","timestamp":1478217600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Karolinska Institutet Foundation"},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["20150070"],"award-info":[{"award-number":["20150070"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Swedish Cancer Society","award":["140395"],"award-info":[{"award-number":["140395"]}]},{"name":"The Cancer and Allergy Foundation","award":["150431"],"award-info":[{"award-number":["150431"]}]},{"name":"The Cancer Society in Stockholm","award":["151313"],"award-info":[{"award-number":["151313"]}]},{"DOI":"10.13039\/501100002706","name":"AFA F\u00f6rs\u00e4kring","doi-asserted-by":"publisher","award":["130054"],"award-info":[{"award-number":["130054"]}],"id":[{"id":"10.13039\/501100002706","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Celgene Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00262-016-1922-6","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T14:55:38Z","timestamp":1478271338000},"page":"91-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Phase I\u2013II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints"],"prefix":"10.1007","volume":"66","author":[{"given":"Maria","family":"Winqvist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariba","family":"Mozaffari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Eketorp Sylvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotta","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e5kan","family":"Mellstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,4]]},"reference":[{"key":"1922_CR1","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1172\/JCI35017","volume":"118","author":"AG Ramsay","year":"2008","unstructured":"Ramsay AG, Johnson AJ, Lee AM et al (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118:2427\u20132437. doi: 10.1172\/JCI35017","journal-title":"J Clin Invest"},{"key":"1922_CR2","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","volume":"121","author":"JC Riches","year":"2013","unstructured":"Riches JC, Davies JK, McClanahan F et al (2013) T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 121:1612\u20131621. doi: 10.1182\/blood-2012-09-457531","journal-title":"Blood"},{"key":"1922_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00262-005-0675-4","volume":"55","author":"H Mellstedt","year":"2006","unstructured":"Mellstedt H, Choudhury A (2006) T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunol Immunother 55:210\u2013220. doi: 10.1007\/s00262-005-0675-4","journal-title":"Cancer Immunol Immunother"},{"key":"1922_CR4","doi-asserted-by":"crossref","unstructured":"Palma M, Gentilcore G, Heimersson K et al (2016) T cells in chronic lymphocytic leukemia\u00a0display dysregulated expression of immune checkpoints and activation markers. Haematologica (in press)","DOI":"10.3324\/haematol.2016.151100"},{"key":"1922_CR5","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1038\/bcj.2016.9","volume":"6","author":"A Buhler","year":"2016","unstructured":"B\u00fchler A, Wendtner CM, Kipps TJ et al (2016) Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J 6:e404. doi: 10.1038\/bcj.2016.9","journal-title":"Blood Cancer J"},{"key":"1922_CR6","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","volume":"24","author":"A Chanan-Khan","year":"2006","unstructured":"Chanan-Khan A, Miller KC, Musial L et al (2006) Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24:5343\u20135349. doi: 10.1200\/JCO.2005.05.0401","journal-title":"J Clin Oncol"},{"key":"1922_CR7","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","volume":"111","author":"A Ferrajoli","year":"2008","unstructured":"Ferrajoli A, Lee BN, Schlette EJ et al (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291\u20135297. doi: 10.1182\/blood-2007-12-130120","journal-title":"Blood"},{"key":"1922_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.critrevonc.2015.09.003","volume":"97","author":"R Maffei","year":"2016","unstructured":"Maffei R, Colaci E, Fiorcari S et al (2016) Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. Crit Rev Oncol Hematol 97:291\u2013302. doi: 10.1016\/j.critrevonc.2015.09.003","journal-title":"Crit Rev Oncol Hematol"},{"key":"1922_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/sj.leu.2404869","volume":"22","author":"K Giannopoulos","year":"2008","unstructured":"Giannopoulos K, Schmitt M, Wlasiuk P et al (2008) The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 22:222\u2013224. doi: 10.1038\/sj.leu.2404869","journal-title":"Leukemia"},{"key":"1922_CR10","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/j.1365-2141.2009.08014.x","volume":"148","author":"I Idler","year":"2010","unstructured":"Idler I, Giannopoulos K, Zenz T et al (2010) Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol 148:948\u2013950. doi: 10.1111\/j.1365-2141.2009.08014.x","journal-title":"Br J Haematol"},{"key":"1922_CR11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/039463201102400410","volume":"24","author":"G D\u2019Arena","year":"2011","unstructured":"D\u2019Arena G, Rossi G, Minervini MM et al (2011) Circulating regulatory T cells in \u201cclinical\u201d monoclonal B-cell lymphocytosis. Int J Immunopathol Pharmacol 24:915\u2013923","journal-title":"Int J Immunopathol Pharmacol"},{"key":"1922_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/265840","author":"A Acebes-Huerta","year":"2014","unstructured":"Acebes-Huerta A, Huergo-Zapico L, Gonzalez-Rodriguez AP et al (2014) Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res Int. doi: 10.1155\/2014\/265840","journal-title":"Biomed Res Int"},{"key":"1922_CR13","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","volume":"187","author":"PA Haslett","year":"1998","unstructured":"Haslett PA, Corral LG, Albert M et al (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885\u20131892","journal-title":"J Exp Med"},{"key":"1922_CR14","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","volume":"103","author":"R LeBlanc","year":"2004","unstructured":"LeBlanc R, Hideshima T, Catley LP et al (2004) Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103:1787\u20131790. doi: 10.1182\/blood-2003-02-0361","journal-title":"Blood"},{"key":"1922_CR15","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","volume":"120","author":"AG Ramsay","year":"2012","unstructured":"Ramsay AG, Clear AJ, Fatah R et al (2012) Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 120:1412\u20131421. doi: 10.1182\/blood-2012-02-411678","journal-title":"Blood"},{"key":"1922_CR16","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1002\/cncr.25983","volume":"117","author":"BN Lee","year":"2011","unstructured":"Lee BN, Gao H, Cohen EN et al (2011) Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 117:3999\u20134008. doi: 10.1002\/cncr.25983","journal-title":"Cancer"},{"key":"1922_CR17","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.4049\/jimmunol.168.10.4914","volume":"168","author":"K Dredge","year":"2002","unstructured":"Dredge K, Marriott JB, Todryk SM et al (2002) Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 168:4914\u20134919","journal-title":"J Immunol"},{"key":"1922_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ et al (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677\u2013704. doi: 10.1146\/annurev.immunol.26.021607.090331","journal-title":"Annu Rev Immunol"},{"key":"1922_CR19","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3324\/haematol.2012.077537","volume":"98","author":"D Brusa","year":"2013","unstructured":"Brusa D, Serra S, Coscia M et al (2013) The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica 98:953\u2013963. doi: 10.3324\/haematol.2012.077537","journal-title":"Haematologica"},{"key":"1922_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3324\/haematol.2013.098459","volume":"99","author":"FJ Gassner","year":"2014","unstructured":"Gassner FJ, Zaborsky N, Neureiter D et al (2014) Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. Haematologica 99:67\u201369. doi: 10.3324\/haematol.2013.098459","journal-title":"Haematologica"},{"key":"1922_CR21","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nri3108","volume":"11","author":"LS Walker","year":"2011","unstructured":"Walker LS, Sansom DM (2011) The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 11:852\u2013863. doi: 10.1038\/nri3108","journal-title":"Nat Rev Immunol"},{"key":"1922_CR22","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.leu.2403907","volume":"19","author":"M Motta","year":"2005","unstructured":"Motta M, Rassenti L, Shelvin BJ et al (2005) Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 19:1788\u20131793. doi: 10.1038\/sj.leu.2403907","journal-title":"Leukemia"},{"key":"1922_CR23","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V et al (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554\u20133561","journal-title":"Blood"},{"key":"1922_CR24","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","volume":"15","author":"A Osterborg","year":"1997","unstructured":"Osterborg A, Dyer MJ, Bunjes D et al (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15:1567\u20131574","journal-title":"J Clin Oncol"},{"key":"1922_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/bjh.12077","volume":"159","author":"SE Sylvan","year":"2012","unstructured":"Sylvan SE, Rossmann E, Mozaffari F et al (2012) Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression. Br J Haematol 159:608\u2013612. doi: 10.1111\/bjh.12077","journal-title":"Br J Haematol"},{"key":"1922_CR26","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2014Working Group 1996 guidelines. Blood 111:5446\u20135456. doi: 10.1182\/blood-2007-06-093906","journal-title":"Blood"},{"key":"1922_CR27","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1080\/10428190701573257","volume":"48","author":"CS Tam","year":"2007","unstructured":"Tam CS, O\u2019Brien S, Lerner S et al (2007) The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 48:1931\u20131939. doi: 10.1080\/10428190701573257","journal-title":"Leuk Lymphoma"},{"key":"1922_CR28","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1080\/10428190902763533","volume":"50","author":"T Zenz","year":"2009","unstructured":"Zenz T, Mohr J, Edelmann J et al (2009) Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma 50:510\u2013513. doi: 10.1080\/10428190902763533","journal-title":"Leuk Lymphoma"},{"key":"1922_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213\u2013223. doi: 10.1056\/NEJMoa1400376","journal-title":"N Engl J Med"},{"key":"1922_CR30","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE et al (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997\u20131007. doi: 10.1056\/NEJMoa1315226","journal-title":"N Engl J Med"},{"key":"1922_CR31","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3109\/10428194.2015.1122783","volume":"57","author":"A Osterborg","year":"2016","unstructured":"Osterborg A, Udvardy M, Zaritskey A et al (2016) Phase III, randomized study of ofatumumab versus physicians\u2019 choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma 57:2037\u20132046. doi: 10.3109\/10428194.2015.1122783","journal-title":"Leuk Lymphoma"},{"key":"1922_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM et al (2016) Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 374:311\u2013322. doi: 10.1056\/NEJMoa1513257","journal-title":"N Engl J Med"},{"key":"1922_CR33","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, Furman RR, Coutre SE et al (2015) Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125:2497\u20132506. doi: 10.1182\/blood-2014-10-606038","journal-title":"Blood"},{"key":"1922_CR34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144576","author":"M Winqvist","year":"2016","unstructured":"Winqvist M, Asklid A, Andersson PO et al (2016) Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. Haematologica. doi: 10.3324\/haematol.2016.144576","journal-title":"Haematologica"},{"key":"1922_CR35","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.2012.42.8623","volume":"31","author":"XC Badoux","year":"2013","unstructured":"Badoux XC, Keating MJ, Wen S et al (2013) Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 31:584\u2013591. doi: 10.1200\/JCO.2012.42.8623","journal-title":"J Clin Oncol"},{"key":"1922_CR36","doi-asserted-by":"crossref","unstructured":"Chanan-Khan A, Zaritskey A, Egyed M (2014) Phase 3 study of oral lenalidomide as maintenance therapy for patients with B-cell chronic lymphocytic leukemia (CLL). ASCO Annual Meeting. J Clin Oncol, 32Suppl; abstract TPS7125 [Abstract], Chigaco, IL, USA","DOI":"10.1200\/jco.2014.32.15_suppl.tps7125"},{"key":"1922_CR37","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.leukres.2016.05.012","volume":"47","author":"JC Chavez","year":"2016","unstructured":"Chavez JC, Piris-Villaespesa M, Dalia S et al (2016) Results of a phase II study of lenalidomide and rituximab for refractory\/relapsed chronic lymphocytic leukemia. Leuk Res 47:78\u201383. doi: 10.1016\/j.leukres.2016.05.012","journal-title":"Leuk Res"},{"key":"1922_CR38","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1200\/JCO.2013.51.5890","volume":"32","author":"DF James","year":"2014","unstructured":"James DF, Werner L, Brown JR et al (2014) Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol 32:2067\u20132073. doi: 10.1200\/JCO.2013.51.5890","journal-title":"J Clin Oncol"},{"key":"1922_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/ejh.12714","volume":"97","author":"C Maurer","year":"2016","unstructured":"Maurer C, Pflug N, Bahlo J et al (2016) Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. Eur J Haematol 97:253\u2013260. doi: 10.1111\/ejh.12714","journal-title":"Eur J Haematol"},{"key":"1922_CR40","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1158\/1078-0432.CCR-15-2476","volume":"22","author":"C Vitale","year":"2016","unstructured":"Vitale C, Falchi L, Ten Hacken E et al (2016) Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia: correlation between responses and immune characteristics. Clin Cancer Res 22:2359\u20132367. doi: 10.1158\/1078-0432.CCR-15-2476","journal-title":"Clin Cancer Res"},{"key":"1922_CR41","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3109\/10428194.2015.1128540","volume":"57","author":"CM Wendtner","year":"2016","unstructured":"Wendtner CM, Hallek M, Fraser GA et al (2016) Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma 57:1291\u20131299. doi: 10.3109\/10428194.2015.1128540","journal-title":"Leuk Lymphoma"},{"key":"1922_CR42","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.leukres.2014.05.011","volume":"38","author":"K Maddocks","year":"2014","unstructured":"Maddocks K, Ruppert AS, Browning R et al (2014) A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. Leuk Res 38:1025\u20131029. doi: 10.1016\/j.leukres.2014.05.011","journal-title":"Leuk Res"},{"key":"1922_CR43","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/cei.12343","volume":"177","author":"A Busch","year":"2014","unstructured":"Busch A, Zeh D, Janzen V et al (2014) Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. Clin Exp Immunol 177:439\u2013453. doi: 10.1111\/cei.12343","journal-title":"Clin Exp Immunol"},{"key":"1922_CR44","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.4049\/jimmunol.1002460","volume":"187","author":"B Neuber","year":"2011","unstructured":"Neuber B, Herth I, Tolliver C et al (2011) Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma. J Immunol 187:1047\u20131056. doi: 10.4049\/jimmunol.1002460","journal-title":"J Immunol"},{"key":"1922_CR45","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/sj.leu.2403258","volume":"18","author":"J Lundin","year":"2004","unstructured":"Lundin J, Porwit-MacDonald A, Rossmann ED et al (2004) Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 18:484\u2013490. doi: 10.1038\/sj.leu.2403258","journal-title":"Leukemia"},{"key":"1922_CR46","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.4049\/jimmunol.1301926","volume":"191","author":"X Zhang","year":"2013","unstructured":"Zhang X, Tao Y, Chopra M et al (2013) Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol 191:5867\u20135874. doi: 10.4049\/jimmunol.1301926","journal-title":"J Immunol"},{"key":"1922_CR47","doi-asserted-by":"crossref","unstructured":"Ding W, Dong H, Call TG (2015) PD-1 Blockade with Pembrolizumab (MK-3475) in relapsed\/refractory CLL including Richter transformation: an early efficacy report from a phase 2 trial (MC1485). 57th American Society of Hematology (ASH), 126:23 #834 [Abstract], Orlando, FL, USA","DOI":"10.1182\/blood.V126.23.834.834"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1922-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-016-1922-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1922-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T04:06:34Z","timestamp":1601179594000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-016-1922-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,4]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["1922"],"URL":"https:\/\/doi.org\/10.1007\/s00262-016-1922-6","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2016,11,4]]}}}